🇺🇸 FDA
Patent

US 10875893

Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods

granted A61KA61K38/00A61K38/005

Quick answer

US patent 10875893 (Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods) held by Apellis Pharmaceuticals, Inc. expires Mon Dec 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Apellis Pharmaceuticals, Inc.
Grant date
Tue Dec 29 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
9
CPC classes
A61K, A61K38/00, A61K38/005, A61K38/10, A61K47/542